Neurology Specific Literature Search   
 
[home][thesaurus]
    
Click Here to return To Results

 

Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
See this aricle in Pubmed

Article Abstract
Based on available evidence, Andexanet represents low value for reversal of factor Xa-associated ICrH; however, there is substantial uncertainty reflecting the currently available data. Further comparative evidence and costing data will become available in the future with randomized trial of Andexanet versus PCC.
 
Related Tags
(click to filter results - removes previous filter)

adverse drug reaction
andexanet
anticoagulant,reversal of
apixaban
complications
cost
cost effectiveness
efficacy
factor Xa inhibitor
intracerebral hemorrhage
non-vitamin K antagonist oral anticoagulants
practice guidelines
prothrombin complex concentrate
safety
treatment of neurologic disorder

Click Here to return To Results